Kevin White
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Kevin White has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
- Alexander Witkowski
Department of Dermatology Oregon Health and Science University Portland Oregon USA
2 shared publications - Alfons Krol
Department of Dermatology, Oregon Health & Science University, Portland, Oregon, United States of America
2 shared publications - Julie Dhossche
Department of Dermatology Oregon Health & Science University Portland Oregon USA
2 shared publications - Ludmila Perelygina
Division of Viral Diseases Centers for Disease Control and Prevention Atlanta Georgia USA
2 shared publications - Tracy Funk
Department of Dermatology Oregon Health & Science University Portland Oregon USA
2 shared publications A. G. Ortega‐Loayza
Department of Dermatology Oregon Health and Science University Portland OR USA
1 shared publication
Latest Publications
- 1 October 2026
- Published by Wolters Kluwer Health in The American Journal of Dermatopathology
Congenital Adnexal Carcinoma with Cribriform Pattern in a Pediatric Patient
Primary cutaneous adnexal carcinomas are exceedingly rare in pediatric patients. A 12-year-old girl presented to the dermatology clinic with a congenital subcutaneous nodule on the left buttock. The patient underwent wide local excision, and histopathologic findings demonstrated large nodular aggregates of atypical basaloid cells with a sieve-like pattern. Immunohistochemical stains were positive for p63, AE1/AE3, β-catenin, and EMA. CK7, CK20, CD117, SOX-10, and Ber-Ep4 were negative. To the best of our knowledge upon review of the literature, we describe a new entity of an adnexal carcinoma with a cribriform pattern in a pediatric patient. Although there was no clinical evidence of recurrence at follow-up, the biologic potential of this tumor is unknown.
- 1 October 2026
- Published by Wolters Kluwer Health in The American Journal of Dermatopathology
Congenital Adnexal Carcinoma with Cribriform Pattern in a Pediatric Patient
Primary cutaneous adnexal carcinomas are exceedingly rare in pediatric patients. A 12-year-old girl presented to the dermatology clinic with a congenital subcutaneous nodule on the left buttock. The patient underwent wide local excision, and histopathologic findings demonstrated large nodular aggregates of atypical basaloid cells with a sieve-like pattern. Immunohistochemical stains were positive for p63, AE1/AE3, β-catenin, and EMA. CK7, CK20, CD117, SOX-10, and Ber-Ep4 were negative. To the best of our knowledge upon review of the literature, we describe a new entity of an adnexal carcinoma with a cribriform pattern in a pediatric patient. Although there was no clinical evidence of recurrence at follow-up, the biologic potential of this tumor is unknown.
- 6 April 2025
- Published by Wiley in Journal of Cutaneous Pathology
- Vol. 52 (6) , 428-431
Hypopigmented Junctional BAP1‐Inactivated Melanocytoma: A Paradigm Shift
Since their original description by Wiesner et al., the spectrum of clinical, histopathologic, and molecular findings of BAP1 (BRCA1‐associated protein 1)‐inactivated melanocytomas has been more fully characterized. Herein, we report an exceptional presentation of multiple junctional melanocytic BAP1‐inactivated melanocytomas with a clinically hypopigmented appearance in a patient. Targeted DNA sequencing demonstrated the same BAP1 frameshift mutation (BAP1 p.R59f) in three different lesions. One of the specimens also displayed two truncating mutations in NF1 (NF1 p.Q129* and NF1 p.Q1801*) at 8%–9% mutant allele frequency. To our knowledge, BIM confined entirely to the epidermis, and multiple BIMs presenting in hypopigmented fashion have not been widely reported previously.
- 6 April 2025
- Published by Wiley in Journal of Cutaneous Pathology
- Vol. 52 (6) , 428-431
Hypopigmented Junctional BAP1‐Inactivated Melanocytoma: A Paradigm Shift
Since their original description by Wiesner et al., the spectrum of clinical, histopathologic, and molecular findings of BAP1 (BRCA1‐associated protein 1)‐inactivated melanocytomas has been more fully characterized. Herein, we report an exceptional presentation of multiple junctional melanocytic BAP1‐inactivated melanocytomas with a clinically hypopigmented appearance in a patient. Targeted DNA sequencing demonstrated the same BAP1 frameshift mutation (BAP1 p.R59f) in three different lesions. One of the specimens also displayed two truncating mutations in NF1 (NF1 p.Q129* and NF1 p.Q1801*) at 8%–9% mutant allele frequency. To our knowledge, BIM confined entirely to the epidermis, and multiple BIMs presenting in hypopigmented fashion have not been widely reported previously.
- 6 March 2025
- Published by Wiley in Pediatric Dermatology
- Vol. 42 (3) , 640-642
Pediatric Dermatology, Pruritic Annular Vesiculobullous Plaques in a 10‐Year‐Old Female
- 6 March 2025
- Published by Wiley in Pediatric Dermatology
- Vol. 42 (3) , 640-642
Pediatric Dermatology, Pruritic Annular Vesiculobullous Plaques in a 10‐Year‐Old Female
- 28 January 2021
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 46 (5) , 924-926
Granuloma annulare following initiation of interleukin‐17a antagonist
The introduction of biologics has rapidly expanded treatment options for patients suffering from severe plaque psoriasis. Currently, the mainstay of biologic therapy for psoriasis centers around three key classes: Anti‐tumor necrosis factor (TNF), Anti‐Interleukin (IL)‐23, and Anti‐IL‐17, such as Secukinumab and Ixekizumab. Though generally considered to have favorable safety profiles, there have been growing reports of dermatologic adverse events in the setting of biologic therapy initiation.
- 28 January 2021
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 46 (5) , 924-926
Granuloma annulare following initiation of interleukin‐17a antagonist
The introduction of biologics has rapidly expanded treatment options for patients suffering from severe plaque psoriasis. Currently, the mainstay of biologic therapy for psoriasis centers around three key classes: Anti‐tumor necrosis factor (TNF), Anti‐Interleukin (IL)‐23, and Anti‐IL‐17, such as Secukinumab and Ixekizumab. Though generally considered to have favorable safety profiles, there have been growing reports of dermatologic adverse events in the setting of biologic therapy initiation.
- Open Access
- 26 August 2020
- Published by F1000 Research Ltd in F1000Research
- Vol. 9, 668
Case Report: Chilblains-like lesions (COVID-19 toes) during the pandemic - is there a diagnostic window?
The COVID-19 outbreak caused by the novel coronavirus, SARS-CoV-2, typically presents with symptoms including fever, cough, headache, myalgia, asthenia, anosmia, diarrhea, and sometimes pneumonia, which can be fatal. Recently, new dermatologic findings have been described in association with the disease that can potentially be a distinguishing feature of infection. One such feature resembles chilblains and this case report represents a presentation of this feature with a 48-year-old female with violaceous lesions with surrounding pink erythema on her toes who tested negative for COVID-19.
- 26 August 2020
- Published by F1000 Research Ltd in F1000Research
- Vol. 9, 668
Open AccessCase Report: Chilblains-like lesions (COVID-19 toes) during the pandemic - is there a diagnostic window?
The COVID-19 outbreak caused by the novel coronavirus, SARS-CoV-2, typically presents with symptoms including fever, cough, headache, myalgia, asthenia, anosmia, diarrhea, and sometimes pneumonia, which can be fatal. Recently, new dermatologic findings have been described in association with the disease that can potentially be a distinguishing feature of infection. One such feature resembles chilblains and this case report represents a presentation of this feature with a 48-year-old female with violaceous lesions with surrounding pink erythema on her toes who tested negative for COVID-19.
- Open Access
- 2 July 2020
- Published by F1000 Research Ltd in F1000Research
- Vol. 9, 668
Case Report: Cutaneous chilblains-like lesions (CCLL) versus COVID-19 toes during the pandemic. Confocal findings and proposal for new acronym, CCLL – is there a diagnostic window?
The COVID-19 outbreak caused by the novel coronavirus, SARS-CoV-2, typically presents with symptoms including fever, cough, headache, myalgia, asthenia, anosmia, diarrhea, and sometimes pneumonia, which can be fatal. Recently, new dermatologic findings have been described in association with the disease that can potentially be a distinguishing feature of infection. One such feature resembles chilblains and this case report represents a unique presentation of this feature.
- 2 July 2020
- Published by F1000 Research Ltd in F1000Research
- Vol. 9, 668
Open AccessCase Report: Cutaneous chilblains-like lesions (CCLL) versus COVID-19 toes during the pandemic. Confocal findings and proposal for new acronym, CCLL – is there a diagnostic window?
The COVID-19 outbreak caused by the novel coronavirus, SARS-CoV-2, typically presents with symptoms including fever, cough, headache, myalgia, asthenia, anosmia, diarrhea, and sometimes pneumonia, which can be fatal. Recently, new dermatologic findings have been described in association with the disease that can potentially be a distinguishing feature of infection. One such feature resembles chilblains and this case report represents a unique presentation of this feature.
- 1 February 2020
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 20 (2) , e39-e42
Management of Cutaneous T-Cell Lymphoma/Mycosis Fungoides Occurring in the Setting of Solid Organ Transplantation: Report of 2 Cases
- 1 February 2020
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 20 (2) , e39-e42
Management of Cutaneous T-Cell Lymphoma/Mycosis Fungoides Occurring in the Setting of Solid Organ Transplantation: Report of 2 Cases
- Open Access
- 1 January 2020
- Published by California Digital Library (CDL) in Dermatology Online Journal
- Vol. 26 (1)
Ulcerative C2 neurocutaneous dysesthesia (trigeminal trophic syndrome in an alternative distribution)
Trigeminal trophic syndrome is an uncommon condition characterized by paresthesia, itch, and self-inflicted wounds following the trigeminal dermatome(s). Similar processes adhering to cervical nerve distributions have been reported, calling into question the specificity of trigeminal trophic syndrome for the trigeminal network. Herein, we report patient with trigeminal trophic syndrome adhering to the C2 dermatome, a previously unreported distribution.
- 1 January 2020
- Published by California Digital Library (CDL) in Dermatology Online Journal
- Vol. 26 (1)
Open AccessUlcerative C2 neurocutaneous dysesthesia (trigeminal trophic syndrome in an alternative distribution)
Trigeminal trophic syndrome is an uncommon condition characterized by paresthesia, itch, and self-inflicted wounds following the trigeminal dermatome(s). Similar processes adhering to cervical nerve distributions have been reported, calling into question the specificity of trigeminal trophic syndrome for the trigeminal network. Herein, we report patient with trigeminal trophic syndrome adhering to the C2 dermatome, a previously unreported distribution.
- Open Access
- 28 October 2019
- Published by Public Library of Science (PLoS) in PLOS Pathogens
- Vol. 15 (10) , e1008080
Infectious vaccine-derived rubella viruses emerge, persist, and evolve in cutaneous granulomas of children with primary immunodeficiencies
Rubella viruses (RV) have been found in an association with granulomas in children with primary immune deficiencies (PID). Here, we report the recovery and characterization of infectious immunodeficiency-related vaccine-derived rubella viruses (iVDRV) from diagnostic skin biopsies of four patients. Sequence evolution within PID hosts was studied by comparison of the complete genomic sequences of the iVDRVs with the genome of the vaccine virus RA27/3. The degree of divergence of each iVDRV correlated with the duration of persistence indicating continuous intrahost evolution. The evolution rates for synonymous and nonsynonymous substitutions were estimated to be 5.7 x 10−3 subs/site/year and 8.9 x 10−4 subs/site/year, respectively. Mutational spectra and signatures indicated a major role for APOBEC cytidine deaminases and a secondary role for ADAR adenosine deaminases in generating diversity of iVDRVs. The distributions of mutations across the genes and 3D hotspots for amino acid substitutions in the E1 glycoprotein identified regions that may be under positive selective pressure. Quasispecies diversity was higher in granulomas than in recovered infectious iVDRVs. Growth properties of iVDRVs were assessed in WI-38 fibroblast cultures. None of the iVDRV isolates showed complete reversion to wild type phenotype but the replicative and persistence characteristics of iVDRVs were different from those of the RA27/3 vaccine strain, making predictions of iVDRV transmissibility and teratogenicity difficult. However, detection of iVDRV RNA in nasopharyngeal specimen and poor neutralization of some iVDRV strains by sera from vaccinated persons suggests possible public health risks associated with iVDRV carriers. Detection of IgM antibody to RV in sera of two out of three patients may be a marker of virus persistence, potentially useful for identifying patients with iVDRV before development of lesions. Studies of the evolutionary dynamics of iVDRV during persistence will contribute to development of infection control strategies and antiviral therapies. Primary immunodeficiency diseases (PID) are caused by genetic defects and lead to serious problems including chronic granulomas (abnormal collections (nodules) of inflammatory cells), sometimes lasting for decades and sometimes leading to severe ulcers. Initial reports (2014–2016), including our report of a blinded study using ultrasensitive virus detection in biopsies, proved the association between granuloma of the skin in PID patients and rubella virus. The viruses in these reports and the current report were derived from a widely used vaccine strain of the rubella virus. Work reported here shows that these vaccine-derived viruses are biologically different from the vaccine virus and that their genomes have changed. Genomic changes could be analyzed largely because the exact sequence of starting vaccine virus genome was known. These genomic differences are likely generated via mechanisms similar to those occurring during normal circulation of wild type rubella. We present data that newly recognized mechanisms for generation of sequence diversity in viruses (because of cellular deaminases) likely occurs in the generation of these vaccine-derived rubella viruses. Thousands of PID patients in the United States are likely shedding these vaccine-derived rubella viruses. Our work presented here characterizing viruses in diagnostic specimens highlights at least two areas where insufficient work has been done: 1) research on the properties of rubella virus (limited understanding of the antibody binding sites on the virus); 2) controlled research studies to assess the public health impact of viruses in populations with high immunity.
- 28 October 2019
- Published by Public Library of Science (PLoS) in PLOS Pathogens
- Vol. 15 (10) , e1008080
Open AccessInfectious vaccine-derived rubella viruses emerge, persist, and evolve in cutaneous granulomas of children with primary immunodeficiencies
Rubella viruses (RV) have been found in an association with granulomas in children with primary immune deficiencies (PID). Here, we report the recovery and characterization of infectious immunodeficiency-related vaccine-derived rubella viruses (iVDRV) from diagnostic skin biopsies of four patients. Sequence evolution within PID hosts was studied by comparison of the complete genomic sequences of the iVDRVs with the genome of the vaccine virus RA27/3. The degree of divergence of each iVDRV correlated with the duration of persistence indicating continuous intrahost evolution. The evolution rates for synonymous and nonsynonymous substitutions were estimated to be 5.7 x 10−3 subs/site/year and 8.9 x 10−4 subs/site/year, respectively. Mutational spectra and signatures indicated a major role for APOBEC cytidine deaminases and a secondary role for ADAR adenosine deaminases in generating diversity of iVDRVs. The distributions of mutations across the genes and 3D hotspots for amino acid substitutions in the E1 glycoprotein identified regions that may be under positive selective pressure. Quasispecies diversity was higher in granulomas than in recovered infectious iVDRVs. Growth properties of iVDRVs were assessed in WI-38 fibroblast cultures. None of the iVDRV isolates showed complete reversion to wild type phenotype but the replicative and persistence characteristics of iVDRVs were different from those of the RA27/3 vaccine strain, making predictions of iVDRV transmissibility and teratogenicity difficult. However, detection of iVDRV RNA in nasopharyngeal specimen and poor neutralization of some iVDRV strains by sera from vaccinated persons suggests possible public health risks associated with iVDRV carriers. Detection of IgM antibody to RV in sera of two out of three patients may be a marker of virus persistence, potentially useful for identifying patients with iVDRV before development of lesions. Studies of the evolutionary dynamics of iVDRV during persistence will contribute to development of infection control strategies and antiviral therapies. Primary immunodeficiency diseases (PID) are caused by genetic defects and lead to serious problems including chronic granulomas (abnormal collections (nodules) of inflammatory cells), sometimes lasting for decades and sometimes leading to severe ulcers. Initial reports (2014–2016), including our report of a blinded study using ultrasensitive virus detection in biopsies, proved the association between granuloma of the skin in PID patients and rubella virus. The viruses in these reports and the current report were derived from a widely used vaccine strain of the rubella virus. Work reported here shows that these vaccine-derived viruses are biologically different from the vaccine virus and that their genomes have changed. Genomic changes could be analyzed largely because the exact sequence of starting vaccine virus genome was known. These genomic differences are likely generated via mechanisms similar to those occurring during normal circulation of wild type rubella. We present data that newly recognized mechanisms for generation of sequence diversity in viruses (because of cellular deaminases) likely occurs in the generation of these vaccine-derived rubella viruses. Thousands of PID patients in the United States are likely shedding these vaccine-derived rubella viruses. Our work presented here characterizing viruses in diagnostic specimens highlights at least two areas where insufficient work has been done: 1) research on the properties of rubella virus (limited understanding of the antibody binding sites on the virus); 2) controlled research studies to assess the public health impact of viruses in populations with high immunity.
- Open Access
- 1 July 2019
- Published by American Medical Association (AMA) in JAMA Dermatology
- Vol. 155 (7) , 859-861
Cutaneous Granulomatous Disease With Presence of Rubella Virus in Lesions
This case report describes 2 children with cutaneous granulomatous eruptions and rubella virus present in the lesions.
- 1 July 2019
- Published by American Medical Association (AMA) in JAMA Dermatology
- Vol. 155 (7) , 859-861
Open AccessCutaneous Granulomatous Disease With Presence of Rubella Virus in Lesions
This case report describes 2 children with cutaneous granulomatous eruptions and rubella virus present in the lesions.